SPOTLIGHT: Speedel halts trial

Shares of Switzerland's Speedel were hit hard by yesterday's announcement that the company was halting a trial of its diabetes therapy Avosentan after patients receiving the drug experienced excessive fluid retention. Speedel CEO Alice Huxley said that the company may change the design of the trial to eliminate the side effect. Report